Occam recently recruited Lisa Deschamps to AviadoBio. She takes the helm of this neuro gene therapy company based on the scientific research of Chris Shaw of King’s College London after having had a distinguished career at Novartis in a variety of senior executive management positions in neuroscience and gene therapy. In addition to bringing deep content knowledge to Aviado, Lisa has also provided leadership for the company’s recently successful $80 million financing, bringing in new investors including NEA. For more information, see here.